Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study - EHESP - École des hautes études en santé publique
Journal Articles Multiple Sclerosis and Related Disorders Year : 2022

Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study

Dorothée Videt
  • Function : Author

Abstract

Reactivation of Multiple Sclerosis (MS) activity has been described after fingolimod cessation. Because of its contra indication during pregnancy, switch towards lower efficacy treatments are frequent in MS patients with childbearing desire but expose them to a risk of disease reactivation. In this retrospective study including 44 women with MS, a significant increase of the median annualized relapse rate was found in the year following fingolimod discontinuation compared to the period before (p < 0.0001), and 57% of women experienced at least one relapse. When considering to start fingolimod, particular attention should be paid to women with a short-term pregnancy desire
Fichier principal
Vignette du fichier
Callens et al - 2022 - Disease reactivation after fingolimod cessation.pdf (253.62 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03753568 , version 1 (29-03-2023)

Licence

Identifiers

Cite

Alix Callens, Soline Leblanc, Emmanuelle Le Page, Gilles Edan, Aurore Jourdain, et al.. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. Multiple Sclerosis and Related Disorders, 2022, 66, pp.104066. ⟨10.1016/j.msard.2022.104066⟩. ⟨hal-03753568⟩
124 View
87 Download

Altmetric

Share

More